LOS ANGELES, Oct. 23, 2024 – The Schall Law Firm, a distinguished advocate for shareholder
rights, has raised a clarion call to ALLR investors about a class action lawsuit confronting Allarity
Therapeutics, Inc. (“Allarity” or “the Company”) ALLR, for alleged violations of securities laws dating
back almost a century – to the Securities Exchange Act of 1934.
Investors who transacted in the Company’s securities between May 17,
2022, and July 19, 2024 – encompassing the “Class Period” – are being urged to establish contact with the
legal counsel before the impending deadline of November 12, 2024.
In the wake of purported financial distress, shareholders who bore
losses are beseeched to come forward and take part in the legal proceedings.
The accusatory Complaint alleges that Allarity Therapeutics and its
top brass disseminated deceptive information in the market. By allegedly partaking in illicit activities
concerning Dovitinib NDA and/or the Dovitinib-DRP PMA, the company aroused regulatory and legal suspicion,
jeopardizing its repute. While supposedly downplaying the repercussions of an inquiry once initiated, Allarity
created an ambiance of false hope which reportedly led investors astray, engendering substantial financial
strains.
Investors are urged to consider their legal options to recuperate
incurred losses amid this turmoil, emphasizing the arduous journey to reclaim financial stability after
being blindsided by corporate malfeasance.
The Schall Law Firm is widely recognized for its global advocacy on
securities litigation pertaining to shareholder rights, ushering in a new era of transparency and corporate
accountability.
Kindly note that the statements in this press release may fall under
the purview of Attorney Advertising in select jurisdictions, abiding by the prevailing legal statutes and
ethical provisions.
CONTACT:
The Schall Law Firm
Brian Schall, Esq.,
Office: 310-301-3335
View
original content to download multimedia:Full Article Here
SOURCE The Schall Law Firm